Global Partners L.P. (GLP)
NYSE NYSE Primary 
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, pitching it to one day compete in a >$150bn market. Viking's strong financial position, upcoming Phase 3 trials, and potential oral formulation of VK-2735 justify upgrading the stock to a “Buy.”.
GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Biotech stock plays outside of GLP-1 weight-loss market
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand for GLP-1 weight-loss drugs has led the biotech sector to reach new heights over the last year, and Seigerman believes the trend is as "hot as ever.
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.
Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations -CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time SAN DIEGO, CA / ACCESSWIRE / September 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user friendly and affordable design, today announced an update on its proof-of-concept study in a high-fat diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies.
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be safe and effective for kids as young as 6 years of age.
Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024
Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.
4 Stocks That Boosted Their Bottom Line with Beef
The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorbitant out-of-pocket costs and limited health insurance coverage, the popularity of high protein diets like keto or carnivore continues to gain popularity as a natural method to lose weight.
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment.
